View:
Download DOC
Download PDF
Download XLS
Download XBRL
iex-20200723
0000832101false00008321012020-07-232020-07-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of report: July 23, 2020
(Date of earliest event reported)
IDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1023536-3555336
(State or other jurisdiction (Commission File Number)(IRS Employer
of incorporation)Identification No.)
1925 W. Field Court, Suite 200
Lake Forest, Illinois 60045
(Address of principal executive offices, including zip code)
(847) 498-7070
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $.01 per shareIEXNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 – Results of Operations and Financial Condition.

On July 23, 2020, IDEX Corporation (the “Company”) issued a press release announcing financial results for the period ended June 30, 2020.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report furnished pursuant to Item 2.02 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Item 7.01 – Regulation FD Disclosure.

Q2 2020 Presentation Slides

Presentation slides discussing IDEX Corporation’s quarterly operating results are attached to this Current Report on Form 8-K as Exhibit 99.2 and are incorporated herein by reference.

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand the future prospects of a company and make informed investment decisions. This Current Report and the Exhibits hereto may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated continuing effects of the coronavirus pandemic, including with respect to the Company's sales, facility closures, supply chains and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report. The risks and uncertainties include, but are not limited to, the following: the duration of the coronavirus pandemic and the continuing effects of the coronavirus on our ability to operate our business and facilities, on our customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company's most recent annual report on Form 10-K and the Company's subsequent quarterly reports filed with the Securities and Exchange Commission (SEC) as well as the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included in this Current Report and the Exhibits hereto are only made as of the date of this Current Report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented herein.

The information in this Current Report furnished pursuant to Items 7.01 and 9.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of


that Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 9.01 – Financial Statements and Exhibits.

(a)Exhibits

99.1 Press release dated July 23, 2020 announcing IDEX Corporation’s quarterly operating results

99.2 Presentation slides of IDEX Corporation’s quarterly operating results



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IDEX CORPORATION
By:/s/  WILLIAM K. GROGAN
William K. Grogan
Senior Vice President and Chief Financial Officer
July 24, 2020


EXHBIT INDEX
Exhibit
Number		Description
Document

https://cdn.kscope.io/5ac70f898fba4f1bf85e00ea18e8ced0-idexlogowtaglinejul341.jpg        

For further information:   TRADED: NYSE (IEX)       EX-99.1     
Investor Contact:    
William K. Grogan       
Senior Vice President and Chief Financial Officer      
(847) 498-7070  

THURSDAY, JULY 23, 2020

IDEX REPORTS SECOND QUARTER RESULTS


LAKE FOREST, IL, JULY 23 - IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended June 30, 2020.

Second Quarter 2020 Highlights
•Cash from operations of $169.5 million led to record quarterly FCF of $161.1 million
•Completed a public offering of $500 million 3.0% Senior Notes
•Operating margin of 19.7%; adjusted operating margin of 21.1%
•Adjusted EBITDA margin of 25.1%

Second Quarter 2020
Orders of $521.9 million were down 17 percent compared with the prior year period (-18 percent organic, +2 percent acquisitions and -1 percent foreign currency translation).

Sales of $561.2 million were down 13 percent compared with the prior year period (-17 percent organic, +5 percent acquisitions and -1 percent foreign currency translation).
Gross margin of 41.8 percent was down 370 basis points compared with the prior year period as a result of reduced volume, business mix, the dilutive impact to margins from the recent acquisitions and a $4.1 million pre-tax fair value inventory step-up charge related to the Flow MD acquisition included in the current year period. Excluding the $4.1 million fair value inventory step-up charge, adjusted gross margin of 42.6 percent was down 290 basis points compared with the adjusted prior year period.

Operating income of $110.6 million resulted in an operating margin of 19.7 percent which was down 450 basis points compared with the prior year period as a result of lower sales volume, the dilutive impact to margins from the recent acquisitions, the fair value inventory step-up charge and higher restructuring expenses in 2020, partially offset by price, restructuring savings and an overall reduction in variable expenses. Excluding the $4.1 million fair value inventory step-up charge and $3.8 million of restructuring expenses, adjusted operating income was $118.5 million with an adjusted operating margin of 21.1 percent, down 340 basis points compared with the adjusted prior year period.

Provision for income taxes of $20.8 million in the second quarter of 2020 resulted in an effective tax rate (ETR) of 22.7 percent, which was higher than the prior year period ETR of 21.7 percent primarily due to a decrease in the excess tax benefits related to share-based compensation.

Net income was $70.9 million which resulted in EPS of $0.93. Excluding the fair value inventory step-up charge, restructuring expenses and the loss on early debt redemption, adjusted EPS was $1.10, a decrease of 40 cents, or 27 percent, from the adjusted prior year period EPS. EBITDA of $124.8 million was 22 percent of sales and covered interest expense by 10 times. Adjusted EBITDA of $141.1 million was 25 percent of sales and covered interest expense by over 11 times.



Cash from operations of $169.5 million was up 29% from the prior year period due to favorable working capital, partially offset by lower earnings in the second quarter of 2020. Cash from operations led to free cash flow of $161.1 million, which was up 36 percent from the prior year period and 193 percent of adjusted net income.

The Company repurchased 9,600 shares of common stock for $1.4 million in the second quarter of 2020 at an average price of $149.44.

“I want to thank our employees around the world for their exceptional work over the past several months under the most difficult circumstances. With safety as our first priority, these women and men continued to provide our essential products across the globe while adhering to a myriad of new safety protocols, from taking temperatures to social distancing and face coverings. The second quarter of 2020 was unprecedented, but the resiliency of our businesses and the resolve of our teams were on full display, with strong operating performance and the fast-track development of several new products to support the battle against COVID-19.
The global health pandemic continued to impact our commercial performance, with second quarter organic orders decreasing 18 percent and organic sales decreasing 17 percent. Sales of $561 million drove adjusted operating margin of 21.1 percent and adjusted EPS of $1.10. Our recent acquisitions negatively impacted adjusted gross margin and adjusted operating margin by 100 basis points and 70 basis points, respectively. As expected with the steep decline in revenue, the balance sheet delevered resulting in record quarterly free cash flow of $161 million. We ended the quarter with record cash of $746 million and nearly $800 million available under our revolving credit facility. Our balance sheet and liquidity position are key strengths and we are well positioned to deploy capital when opportunities arise.
Our business continues to demonstrate durability given the mission critical nature of our products. Our businesses and products supporting maintenance, repair and operating fared better than our businesses and products that are more reliant on the deployment of new capital. We believe we hit the bottom in the second quarter, but we still face much uncertainty regarding the future path of the economy due to the evolving global pandemic. As the timing and pace of an economic recovery are uncertain, we are unable to provide detailed financial guidance other than based on currently available information we now expect third quarter organic sales to be down approximately 12 to 17 percent versus prior year."
Andrew K. Silvernail
Chairman and Chief Executive Officer

Second Quarter 2020 Segment Highlights

Fluid & Metering Technologies
•Sales of $219.1 million reflected an 11 percent decrease compared to the second quarter of 2019 (-20 percent organic, +10 percent acquisition and -1 percent foreign currency translation).
•Operating income of $50.9 million resulted in an operating margin of 23.2 percent which was down 690 basis points compared with the prior year period primarily due to lower volume and the impact of the Flow MD acquisition as well as a $4.1 million fair value inventory step-up charge related to the Flow MD acquisition and higher restructuring expenses included in the current year period, partially offset by price, restructuring savings and lower variable costs. Excluding the $4.1 million fair value inventory step-up charge and $1.8 million of restructuring expenses, adjusted operating income was $56.8 million with an adjusted operating margin of 26.0 percent, a 450 basis point decrease compared to the adjusted prior year period.
•EBITDA of $57.8 million resulted in an EBITDA margin of 26.4 percent. Excluding the $4.1 million fair value inventory step-up charge and $1.8 million of restructuring expenses, adjusted EBITDA of


$63.7 million resulted in an adjusted EBITDA margin of 29.1 percent, a 360 basis point decrease compared to the adjusted prior year period primarily due to lower volume.

Health & Science Technologies
•Sales of $215.7 million reflected a 7 percent decrease compared to the second quarter of 2019 (-10 percent organic, +4 percent acquisition and -1 percent foreign currency translation).
•Operating income of $48.0 million resulted in an operating margin of 22.3 percent which was down 210 basis points compared with the prior year period primarily due to lower volume, the impact of the Velcora acquisition and higher restructuring expenses, partially offset by price, restructuring savings and lower variable costs. Excluding $1.2 million of restructuring expenses, adjusted operating income was $49.2 million with an adjusted operating margin of 22.8 percent, a 180 basis point decrease compared to the adjusted prior year period.
•EBITDA of $57.5 million resulted in an EBITDA margin of 26.6 percent. Excluding the $1.2 million of restructuring expenses, adjusted EBITDA of $58.7 million resulted in an adjusted EBITDA margin of 27.2 percent, a 150 basis point decrease compared to the adjusted prior year period primarily due to lower volume.

Fire & Safety/Diversified Products
•Sales of $127.1 million reflected a 23 percent decrease compared to the second quarter of 2019 (-22 percent organic and -1 percent foreign currency translation).
•Operating income of $28.8 million resulted in an operating margin of 22.7 percent which was down 390 basis points compared with the prior year period as a result of lower volume and business mix, partially offset by price and restructuring savings as well as lower variable costs and lower restructuring expenses. Excluding $0.6 million of restructuring expenses, adjusted operating income was $29.4 million with an adjusted operating margin of 23.2 percent, a 390 basis point decrease compared to the adjusted prior year period.
•EBITDA of $32.5 million resulted in an EBITDA margin of 25.6 percent. Excluding the $0.6 million of restructuring expenses, adjusted EBITDA of $33.1 million resulted in an adjusted EBITDA margin of 26.1 percent, a 330 basis point decrease compared to the prior year period primarily due to lower volume.

For the second quarter of 2020, Fluid & Metering Technologies contributed 39 percent of sales, 40 percent of operating income and 39 percent of EBITDA; Health & Science Technologies accounted for 38 percent of sales, 37 percent of operating income and 39 percent of EBITDA; and Fire & Safety/Diversified Products represented 23 percent of sales, 23 percent of operating income and 22 percent of EBITDA.

Corporate Costs
Corporate costs decreased to $17.2 million in the second quarter of 2020 from $19.2 million in the second quarter of 2019 primarily as a result of tightly controlling discretionary spending, restructuring savings and lower variable costs in 2020.

Debt Offering and Redemption
On April 29, 2020, the Company completed a public offering of $500.0 million 3.0% Senior Notes due May 1, 2030. The net proceeds from the offering were $494.9 million. The net proceeds were used to redeem and repay the $300.0 million 4.5% Senior Notes due December 15, 2020 and the related “make-whole” redemption premium of $6.8 million. The Company also recognized $1.6 million of deferred costs related to the 4.5% Senior Notes for a total loss on early debt redemption of $8.4 million which was recorded within Other (income) expense - net.

New Joint Venture
On May 12, 2020, a subsidiary of IDEX entered into a joint venture agreement with a third party to form a limited liability company (the "Joint Venture") that will manufacture and sell high performance elastomer seals for the oil and gas industry to customers within the Kingdom of Saudi Arabia as well as for the export market. The Company will contribute $0.6 million and will own 55% of the share capital while the


third party partner will contribute $0.5 million and will own 45% of the share capital. As of June 30, 2020, the Joint Venture had not yet been funded or begun its operations. Since we will control the entity, we expect to consolidate the Joint Venture and record a noncontrolling interest in our financial statements once funding occurs and operations begin, both of which are currently expected to occur during the third quarter of 2020.

COVID-19 Impact
The Company continues to help in the fight against COVID-19 with several of our businesses playing critical roles in keeping essential activities operating. We also continue to be focused on making sure our employees are safe and our operations have the ability to deliver the products needed to support the COVID-19 battle. Most of our sites are considered essential businesses and have remained open during the pandemic. However, the virus did cause several of our sites to temporarily shut down for cleaning due to employees testing positive for COVID-19. All such sites returned to operations within a short period of time. COVID-19 and the enacted containment measures have adversely affected our business and results of operations and the businesses of our customers, who are purchasing less products in response to the economic conditions caused by COVID-19. The Company expects the months ahead will remain challenging as this global pandemic continues and, based on currently available information and management's current expectations, the Company anticipates that organic sales will be down approximately 12 to 17 percent in the third quarter of 2020. Based on management's current expectations, we believe our strong balance sheet, with over $1.5 billion of liquidity and gross leverage of 1.6 times, will provide IDEX the necessary capital to navigate the COVID-19 pandemic for the foreseeable future. Additionally, IDEX has implemented certain cost reduction actions, including employee reductions and has maintained a tight cost control environment.

Non-U.S. GAAP Measures of Financial Performance
The Company supplements certain U.S. GAAP financial performance metrics with non-U.S. GAAP financial performance metrics in order to provide investors with better insight and increased transparency while also allowing for a more comprehensive understanding of the financial information used by management in its decision making. Reconciliations of non-U.S. GAAP financial performance metrics to their most comparable U.S. GAAP financial performance metrics are defined and presented below and should not be considered a substitute for, nor superior to, the financial data prepared in accordance with U.S. GAAP. There were no adjustments to U.S. GAAP financial performance metrics other than the items noted below.

•Organic orders and sales are calculated excluding amounts from acquired or divested businesses during the first twelve months of ownership or divestiture and the impact of foreign currency translation.
•Adjusted gross profit is calculated as gross profit plus the fair value inventory step-up charge.
•Adjusted gross margin is calculated as adjusted gross profit divided by net sales.
•Adjusted operating income is calculated as operating income plus the fair value inventory step-up charge plus restructuring expenses.
•Adjusted operating margin is calculated as adjusted operating income divided by net sales.
•Adjusted net income is calculated as net income plus the fair value inventory step-up charge plus restructuring expenses plus the loss on early debt redemption, net of the statutory tax expense or benefit.
•Adjusted EPS is calculated as adjusted net income divided by the diluted weighted average shares outstanding.
•EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. We reconcile EBITDA to net income on a consolidated basis as we do not allocate consolidated interest expense or consolidated provision for income taxes to our segments.
•Adjusted EBITDA is calculated as EBITDA plus the fair value inventory step-up charge plus restructuring expenses plus the loss on early debt redemption.


•Adjusted EBITDA margin is calculated as adjusted EBITDA divided by net sales.
•Free cash flow is calculated as cash flow from operating activities less capital expenditures.

Table 1: Reconciliations of the Change in Net Sales to Organic Net Sales
Three Months Ended June 30, 2020Six Months Ended June 30, 2020
FMTHSTFSDPIDEXFMTHSTFSDPIDEX
Change in net sales(11)%(7)%(23)%(13)%(9)%(4)%(15)%(9)%
 - Net impact from acquisitions10 %4 %— %5 %5 %4 %— %3 %
 - Impact from FX(1)%(1)%(1)%(1)%(1)%(1)%(1)%(1)%
Change in organic net sales(20)%(10)%(22)%(17)%(13)%(7)%(14)%(11)%

Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Margin (dollars in thousands)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Gross profit$234,800  $292,337  $506,756  $576,171  
+ Fair value inventory step-up charge4,107  —  4,107  —  
Adjusted gross profit$238,907  $292,337  $510,863  $576,171  
Net sales$561,249  $642,099  $1,155,711  $1,264,330  
Gross margin41.8 %45.5 %43.8 %45.6 %
Adjusted gross margin42.6 %45.5 %44.2 %45.6 %



Table 3: Reconciliations of Reported-to-Adjusted Operating Income and Margin (dollars in thousands)
Three Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported operating income (loss)$50,938  $48,007  $28,837  $(17,188) $110,594  $74,146  $56,763  $43,614  $(19,240) $155,283  
 + Restructuring expenses1,848  1,184  641  168  3,841  930  330  819  47  2,126  
 + Fair value inventory step-up charge4,107  —  —  —  4,107  —  —  —  —  —  
Adjusted operating income (loss)$56,893  $49,191  $29,478  $(17,020) $118,542  $75,076  $57,093  $44,433  $(19,193) $157,409  
Net sales (eliminations)$219,112  $215,668  $127,076  $(607) $561,249  $246,189  $232,253  $164,043  $(386) $642,099  
Reported operating margin23.2 %22.3 %22.7 %n/m19.7 %30.1 %24.4 %26.6 %n/m24.2 %
Adjusted operating margin26.0 %22.8 %23.2 %n/m21.1 %30.5 %24.6 %27.1 %n/m24.5 %
Six Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported operating income (loss)$117,709  $100,650  $66,874  $(34,698) $250,535  $146,012  $110,917  $83,942  $(37,806) $303,065  
 + Restructuring expenses1,848  1,184  641  168  3,841  930  330  819  47  2,126  
 + Fair value inventory step-up charge4,107  —  —  —  4,107  —  —  —  —  —  
Adjusted operating income (loss)$123,664  $101,834  $67,515  $(34,530) $258,483  $146,942  $111,247  $84,761  $(37,759) $305,191  
Net sales (eliminations)$445,973  $439,727  $271,400  $(1,389) $1,155,711  $488,711  $457,543  $320,202  $(2,126) $1,264,330  
Reported operating margin26.4 %22.9 %24.6 %n/m21.7 %29.9 %24.2 %26.2 %n/m24.0 %
Adjusted operating margin27.7 %23.2 %24.9 %n/m22.4 %30.1 %24.3 %26.5 %n/m24.1 %









Table 4: Reconciliations of Reported-to-Adjusted Net Income and EPS (in thousands, except EPS)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Reported net income$70,864  $113,209  $172,862  $223,477  
 + Restructuring expenses3,841  2,126  3,841  2,126  
 + Tax impact on restructuring expenses(837) (560) (837) (560) 
 + Fair value inventory step-up charge4,107  —  4,107  —  
 + Tax impact on fair value inventory step-up charge(932) —  (932) —  
 + Loss on early debt redemption8,421  —  8,421  —  
 + Tax impact on loss on early debt redemption(1,912) —  (1,912) —  
Adjusted net income$83,552  $114,775  $185,550  $225,043  


Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Reported diluted EPS$0.93  $1.48  $2.27  $2.92  
 + Restructuring expenses0.05  0.03  0.05  0.03  
 + Tax impact on restructuring expenses(0.01) (0.01) (0.01) (0.01) 
 + Fair value inventory step-up charge0.05  —  0.05  —  
 + Tax impact on fair value inventory step-up charge(0.01) —  (0.01) —  
 + Loss on early debt redemption0.11  —  0.11  —  
 + Tax impact on loss on early debt redemption(0.02) —  (0.02) —  
Adjusted diluted EPS$1.10  $1.50  $2.44  $2.94  
Diluted weighted average shares outstanding75,937  76,387  76,198  76,334  

Table 5: Reconciliations of EBITDA to Net Income (dollars in thousands)
Three Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported operating income (loss)$50,938  $48,007  $28,837  $(17,188) $110,594  $74,146  $56,763  $43,614  $(19,240) $155,283  
 - Other (income) expense - net(82) 472  123  5,947  6,460  239  80  (140) (557) (378) 
 + Depreciation and amortization6,809  9,917  3,796  104  20,626  5,640  9,635  3,717  172  19,164  
EBITDA57,829  57,452  32,510  (23,031) 124,760  79,547  66,318  47,471  (18,511) 174,825  
 - Interest expense12,439  11,011  
 - Provision for income taxes20,831  31,441  
 - Depreciation and amortization20,626  19,164  
Reported net income$70,864  $113,209  
Net sales (eliminations)$219,112  $215,668  $127,076  $(607) $561,249  $246,189  $232,253  $164,043  $(386) $642,099  
Reported operating margin23.2 %22.3 %22.7 %n/m19.7 %30.1 %24.4 %26.6 %n/m24.2 %
EBITDA margin26.4 %26.6 %25.6 %n/m22.2 %32.3 %28.6 %28.9 %n/m27.2 %
Six Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
Reported operating income (loss)$117,709  $100,650  $66,874  $(34,698) $250,535  $146,012  $110,917  $83,942  $(37,806) $303,065  
 - Other (income) expense - net684  (59) (192) 7,592  8,025  317  364  365  (1,564) (518) 
 + Depreciation and amortization12,207  20,576  7,555  285  40,623  11,146  19,142  7,179  356  37,823  
EBITDA129,232  121,285  74,621  (42,005) 283,133  156,841  129,695  90,756  (35,886) 341,406  
 - Interest expense23,316  21,932  
 - Provision for income taxes46,332  58,174  
 - Depreciation and amortization40,623  37,823  
Reported net income$172,862  $223,477  
Net sales (eliminations)$445,973  $439,727  $271,400  $(1,389) $1,155,711  $488,711  $457,543  $320,202  $(2,126) $1,264,330  
Reported operating margin26.4 %22.9 %24.6 %n/m21.7 %29.9 %24.2 %26.2 %n/m24.0 %
EBITDA margin29.0 %27.6 %27.5 %n/m24.5 %32.1 %28.3 %28.3 %n/m27.0 %


Table 6 : Reconciliations of EBITDA to Adjusted EBITDA (dollars in thousands)

Three Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
EBITDA(1)
$57,829  $57,452  $32,510  $(23,031) $124,760  $79,547  $66,318  $47,471  $(18,511) $174,825  
 + Restructuring expenses1,848  1,184  641  168  3,841  930  330  819  47  2,126  
 + Fair value inventory step-up charge4,107  —  —  —  4,107  —  —  —  —  —  
+ Loss on early debt redemption —  —  —  8,421  8,421  
Adjusted EBITDA$63,784  $58,636  $33,151  $(14,442) $141,129  $80,477  $66,648  $48,290  $(18,464) $176,951  
Adjusted EBITDA margin29.1 %27.2 %26.1 %n/m25.1 %32.7 %28.7 %29.4 %n/m27.6 %
Six Months Ended June 30,
20202019
FMTHSTFSDPCorporateIDEXFMTHSTFSDPCorporateIDEX
EBITDA(1)
$129,232  $121,285  $74,621  $(42,005) $283,133  $156,841  $129,695  $90,756  $(35,886) $341,406  
 + Restructuring expenses1,848  1,184  641  168  3,841  930  330  819  47  2,126  
 + Fair value inventory step-up charge4,107  —  —  —  4,107  —  —  —  —  —  
+ Loss on early debt redemption—  —  —  8,421  8,421  —  —  —  —  —  
Adjusted EBITDA$135,187  $122,469  $75,262  $(33,416) $299,502  $157,771  $130,025  $91,575  $(35,839) $343,532  
Adjusted EBITDA margin30.3 %27.9 %27.7 %n/m25.9 %32.3 %28.4 %28.6 %n/m27.2 %

(1) EBITDA, a non-GAAP financial measure, is reconciled to net income, its most directly comparable GAAP financial measure, immediately above in Table 5.

Table 7: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (in thousands)

Three Months EndedSix Months Ended
June 30,March 31,June 30,
20202019202020202019
Cash flows from operating activities$169,453  $131,175  $84,760  $254,213  $219,838  
 - Capital expenditures8,323  12,867  12,762  21,085  25,742  
Free cash flow$161,130  $118,308  $71,998  $233,128  $194,096  

Conference Call to be Broadcast over the Internet
IDEX will broadcast its second quarter earnings conference call over the Internet on Friday, July 24, 2020 at 9:30 a.m. CT. Chairman and Chief Executive Officer Andy Silvernail and Senior Vice President and Chief Financial Officer William Grogan will discuss the Company’s recent financial performance and respond to questions from the financial analyst community. IDEX invites interested investors to listen to the call and view the accompanying slide presentation, which will be carried live on its website at www.idexcorp.com. Those who wish to participate should log on several minutes before the discussion begins. After clicking on the presentation icon, investors should follow the instructions to ensure their systems are set up to hear the event and view the presentation slides, or download the correct applications at no charge. Investors will also be able to hear a replay of the call by dialing 877.660.6853 (or 201.612.7415 for international participants) using the ID #13694805.



Forward-Looking Statements
This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated continuing effects of the coronavirus pandemic, including with respect to the Company's sales, facility closures, supply chains and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, revenues, earnings, market conditions, global economies and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: the duration of the coronavirus pandemic and the continuing effects of the coronavirus on our ability to operate our business and facilities, on our customers, on supply chains and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and the Company's results, particularly in light of the low levels of order backlogs it typically maintains; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the Company operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the Company’s most recent annual report on Form 10-K and the Company's subsequent quarterly reports filed with the SEC as well as the other risks discussed in the Company’s filings with the SEC. The forward-looking statements included here are only made as of the date of this news release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX
IDEX (NYSE: IEX) is a company that has undoubtedly touched your life in some way. In fact, IDEX businesses make thousands of products that are mission-critical components in everyday activities. Chances are the car you’re driving has a BAND-IT® clamp holding your side airbag safely in place. If you were ever in a car accident, a Hurst Jaws of Life® rescue tool may have saved your life. If you or a family member is battling cancer, your doctor may have tested your DNA in a quest to find the best targeted medicine for you. It’s likely your DNA test was run on equipment that contains components made by our growing IDEX Health & Science team. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call 40 diverse businesses around the world part of the IDEX family. With 7,000 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global $2+ billion company committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX”.

For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com.



(Financial reports follow)


IDEX CORPORATION
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2020201920202019
Net sales$561,249  $642,099  $1,155,711  $1,264,330  
Cost of sales326,449  349,762  648,955  688,159  
Gross profit234,800  292,337  506,756  576,171  
Selling, general and administrative expenses120,365  134,928  252,380  270,980  
Restructuring expenses3,841  2,126  3,841  2,126  
Operating income110,594  155,283  250,535  303,065  
Other (income) expense - net6,460  (378) 8,025  (518) 
Interest expense12,439  11,011  23,316  21,932  
Income before income taxes91,695  144,650  219,194  281,651  
Provision for income taxes20,831  31,441  46,332  58,174  
Net income$70,864  $113,209  $172,862  $223,477  
Earnings per Common Share:
Basic earnings per common share$0.94  $1.50  $2.29  $2.96  
Diluted earnings per common share$0.93  $1.48  $2.27  $2.92  
Share Data:
Basic weighted average common shares outstanding75,171  75,460  75,459  75,450  
Diluted weighted average common shares outstanding75,937  76,387  76,198  76,334  


IDEX CORPORATION
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
June 30, 2020December 31, 2019
Assets
Current assets
Cash and cash equivalents$746,348  $632,581  
Receivables - net270,255  298,186  
Inventories324,931  293,467  
Other current assets55,716  37,211  
Total current assets1,397,250  1,261,445  
Property, plant and equipment - net281,852  280,316  
Goodwill and intangible assets - net2,264,958  2,167,776  
Other noncurrent assets129,532  104,375  
Total assets$4,073,592  $3,813,912  
Liabilities and shareholders' equity
Current liabilities
Trade accounts payable$137,413  $138,463  
Accrued expenses225,931  180,290  
Short-term borrowings228  388  
Dividends payable37,735  38,736  
Total current liabilities401,307  357,877  
Long-term borrowings1,044,445  848,864  
Other noncurrent liabilities366,803  343,942  
Total liabilities1,812,555  1,550,683  
Total shareholders' equity2,261,037  2,263,229  
Total liabilities and shareholders' equity$4,073,592  $3,813,912  


IDEX CORPORATION
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Six Months Ended June 30,
20202019
Cash flows from operating activities
Net income$172,862  $223,477  
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization20,591  19,870  
Amortization of intangible assets20,032  17,953  
Amortization of debt issuance expenses976  669  
Share-based compensation expense13,665  14,413  
Deferred income taxes2,421  10,685  
Non-cash interest expense associated with forward starting swaps4,284  3,171  
Changes in (net of the effect from acquisitions):
Receivables34,253  (14,177) 
Inventories(9,529) (21,007) 
Other current assets(18,421) (12,382) 
Trade accounts payable(6,842) 17,276  
Accrued expenses17,776  (39,602) 
Other - net2,145  (508) 
Net cash flows provided by operating activities254,213  219,838  
Cash flows from investing activities
Purchases of property, plant and equipment(21,085) (25,742) 
Acquisition of businesses, net of cash acquired(120,839) —  
Proceeds from disposal of fixed assets2,114  780  
Other - net(636) 501  
Net cash flows used in investing activities(140,446) (24,461) 
Cash flows from financing activities
Borrowings under revolving credit facilities150,000  —  
Proceeds from issuance of 3.0% Senior Notes 499,100  —  
Payment of 4.5% Senior Notes(300,000) —  
Payments under revolving credit facilities (150,000) —  
Payment of make-whole redemption premium(6,756) —  
Debt issuance costs(4,166) —  
Dividends paid(76,498) (71,283) 
Proceeds from stock option exercises13,111  20,761  
Repurchases of common stock(110,342) (54,668) 
Shares surrendered for tax withholding(12,148) (11,509) 
Other - net(251) (1,929) 
Net cash flows provided by (used in) financing activities2,050  (118,628) 
Effect of exchange rate changes on cash and cash equivalents(2,050) 33  
Net increase in cash113,767  76,782  
Cash and cash equivalents at beginning of year632,581  466,407  
Cash and cash equivalents at end of period$746,348  $543,189  


IDEX CORPORATION
Company and Segment Financial Information - Reported
(dollars in thousands)
(unaudited)
 Three Months Ended
June 30, (a)
Six Months Ended
June 30, (a)
2020201920202019
Fluid & Metering Technologies
Net sales$219,112  $246,189  $445,973  $488,711  
Operating income (b)
50,938  74,146  117,709  146,012  
Operating margin23.2 %30.1 %26.4 %29.9 %
EBITDA(c)
$57,829  $79,547  $129,232  $156,841  
EBITDA margin(c)
26.4 %32.3 %29.0 %32.1 %
Depreciation and amortization$6,809  $5,640  $12,207  $11,146  
Capital expenditures1,794  3,350  6,322  6,580  
Health & Science Technologies
Net sales$215,668  $232,253  $439,727  $457,543  
Operating income (b)
48,007  56,763  100,650  110,917  
Operating margin22.3 %24.4 %22.9 %24.2 %
EBITDA(c)
$57,452  $66,318  $121,285  $129,695  
EBITDA margin(c)
26.6 %28.6 %27.6 %28.3 %
Depreciation and amortization$9,917  $9,635  $20,576  $19,142  
Capital expenditures4,955  5,913  10,284  11,217  
Fire & Safety/Diversified Products
Net sales$127,076  $164,043  $271,400  $320,202  
Operating income (b)
28,837  43,614  66,874  83,942  
Operating margin22.7 %26.6 %24.6 %26.2 %
EBITDA(c)
$32,510  $47,471  $74,621  $90,756  
EBITDA margin(c)
25.6 %28.9 %27.5 %28.3 %
Depreciation and amortization$3,796  $3,717  $7,555  $7,179  
Capital expenditures1,310  3,534  4,194  6,487  
Corporate Office and Eliminations
Intersegment sales eliminations$(607) $(386) $(1,389) $(2,126) 
Operating income (b)
(17,188) (19,240) (34,698) (37,806) 
EBITDA(c)
(23,031) (18,511) (42,005) (35,886) 
Depreciation and amortization (d)
104  172  285  356  
Capital expenditures264  70  285  1,458  
Company
Net sales$561,249  $642,099  $1,155,711  $1,264,330  
Operating income110,594  155,283  250,535  303,065  
Operating margin19.7 %24.2 %21.7 %24.0 %
EBITDA(c)
$124,760  $174,825  $283,133  $341,406  
EBITDA margin(c)
22.2 %27.2 %24.5 %27.0 %
Depreciation and amortization (d)
$20,626  $19,164  $40,623  $37,823  
Capital expenditures8,323  12,867  21,085  25,742  


IDEX CORPORATION
Company and Segment Financial Information - Adjusted (Non-GAAP)
(dollars in thousands)
(unaudited)
 Three Months Ended
June 30, (a)
Six Months Ended
June 30, (a)
2020201920202019
Fluid & Metering Technologies
Net sales$219,112  $246,189  $445,973  $488,711  
Adjusted operating income (b)(c)
56,893  75,076  123,664  146,942  
Adjusted operating margin(c)
26.0 %30.5 %27.7 %30.1 %
Adjusted EBITDA(c)
$63,784  $80,477  $135,187  $157,771  
Adjusted EBITDA margin(c)
29.1 %32.7 %30.3 %32.3 %
Depreciation and amortization$6,809  $5,640  $12,207  $11,146  
Capital expenditures1,794  3,350  6,322  6,580  
Health & Science Technologies
Net sales$215,668  $232,253  $439,727  $457,543  
Adjusted operating income (b)(c)
49,191  57,093  101,834  111,247  
Adjusted operating margin(c)
22.8 %24.6 %23.2 %24.3 %
Adjusted EBITDA(c)
$58,636  $66,648  $122,469  $130,025  
Adjusted EBITDA margin(c)
27.2 %28.7 %27.9 %28.4 %
Depreciation and amortization$9,917  $9,635  $20,576  $19,142  
Capital expenditures4,955  5,913  10,284  11,217  
Fire & Safety/Diversified Products
Net sales$127,076  $164,043  $271,400  $320,202  
Adjusted operating income (b)(c)
29,478  44,433  67,515  84,761  
Adjusted operating margin(c)
23.2 %27.1 %24.9 %26.5 %
Adjusted EBITDA(c)
$33,151  $48,290  $75,262  $91,575  
Adjusted EBITDA margin(c)
26.1 %29.4 %27.7 %28.6 %
Depreciation and amortization$3,796  $3,717  $7,555  $7,179  
Capital expenditures1,310  3,534  4,194  6,487  
Corporate Office and Eliminations
Intersegment sales eliminations$(607) $(386) $(1,389) $(2,126) 
Adjusted operating income (b)(c)
(17,020) (19,193) (34,530) (37,759) 
Adjusted EBITDA(c)
(14,442) (18,464) (33,416) (35,839) 
Depreciation and amortization(d)
104  172  285  356  
Capital expenditures264  70  285  1,458  
Company
Net sales$561,249  $642,099  $1,155,711  $1,264,330  
Adjusted operating income(c)
118,542  157,409  258,483  305,191  
Adjusted operating margin(c)
21.1 %24.5 %22.4 %24.1 %
Adjusted EBITDA(c)
$141,129  $176,951  $299,502  $343,532  
Adjusted EBITDA margin(c)
25.1 %27.6 %25.9 %27.2 %
Depreciation and amortization (d)
$20,626  $19,164  $40,623  $37,823  
Capital expenditures8,323  12,867  21,085  25,742  
(a)Three and six month data includes the results of the Velcora acquisition (July 2019) in the Health & Science Technologies segment and the Flow MD acquisition (February 2020) in the Fluid & Metering Technologies segment.
(b)Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations.
(c)
These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the reconciliation tables above
(d)Depreciation and amortization excludes amortization of debt issuance costs.

q22020earningsslidesfina
Second Quarter 2020 Earnings July 24, 2020

 
Agenda IDEX Business Overview • Q2 Overview • COVID-19 • End Market Update Financials • Q2 Performance • Operating Profit • Liquidity Q3 Summary Q&A 2 IDEX Proprietary & Confidential

 
Replay Information • Dial toll–free: 877.660.6853 • International: 201.612.7415 • Conference ID: #13694805 • Log on to: www.idexcorp.com 3 IDEX Proprietary & Confidential

 
Cautionary Statement Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation and discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the anticipated effects of the coronavirus pandemic, including with respect to the Company’s revenues, facility closures and access to capital, capital expenditures, acquisitions, cost reductions, cash flow, cash requirements, revenues, earnings, market conditions, global economies, plant and equipment capacity and operating improvements, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,” “will,” “management believes,” “the company believes,” “the company intends,” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this news release. The risks and uncertainties include, but are not limited to, the following: the duration of the coronavirus pandemic and the effects of the coronavirus on our ability to operate our business and facilities, on our customers and on the U.S. and global economy generally; economic and political consequences resulting from terrorist attacks and wars; levels of industrial activity and economic conditions in the U.S. and other countries around the world; pricing pressures and other competitive factors, and levels of capital spending in certain industries – all of which could have a material impact on order rates and IDEX’s results, particularly in light of the low levels of order backlogs it typically maintains; its ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which the company operates; interest rates; capacity utilization and the effect this has on costs; labor markets; market conditions and material costs; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in the company’s most recent annual report on Form 10-K filed with the SEC and the other risks discussed in the company’s filings with the SEC. The forward-looking statements included in this presentation and discussion are only made as of today’s date, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information in this presentation and discussion. This presentation contains non-GAAP financial information. Reconciliations of non-GAAP measures are included either in this presentation or our earnings release for the six-month period ending June 30, 2020, which is available on our website. 4 IDEX Proprietary & Confidential

 
Business Update IDEX Proprietary & Confidential

 
Q2 Overview We are in this fight! • Employees going above and beyond • Essential products delivered globally • Innovating with Customers Executing in an challenging environment • Operations and Supply Chain performing • Diversified portfolio balancing declines • Record Q2 cash flow generation Controlling the controllable… • Discretionary costs down approximately 50% • Targeted restructuring actions • Key investments made 6 IDEX Proprietary & Confidential

 
Operating our COVID-19 Playbook Focus on our people around the world and actions taken to Safety keep people physically, emotionally, and financially safe Prepared to manage our businesses in a volatile environment; Business how we handle supply chain, internal operations and customer Continuity disruptions Managing cash flow, strong liquidity position, and our staying Liquidity power Playing Adapting to help with the COVID-19 fight and what we are Offense doing to position ourselves for the recovery 7 IDEX Proprietary & Confidential

 
COVID-19 Microfluidics IDEX Materials Processing Technologies’ (MPT) Microfluidizer ® is a key technology being used in the development of a COVID-19 vaccine, specifically enabling the creation of vaccine adjuvants. Adjuvants added to the vaccine allow the body to produce a better immune response The adjuvant also allows the vaccine manufacturer to produce more vaccine doses with less antigen 8

 
Market Update FLUID & METERING HEALTH & SCIENCE FIRE & SAFETY / TECHNOLOGY TECHNOLOGY DIVERSIFIED 2020 Q2 REVENUE $219M $216M $127M % OF TOTAL 39% 38% 23% Industrial Life Sciences Dispensing Chemical Analytical Instrumentation Rescue Energy Industrial / Other Fire END MARKETS Water Food / Pharma Automotive Agriculture Auto Industrial / Other Semiconductor 9 IDEX Proprietary & Confidential - Down < (5%) vs PY - Down (5%) – (15%) vs PY - Down > (15%) vs PY

 
Financials IDEX Proprietary & Confidential

 
IDEX Q2 Financial Performance (Dollars in millions, excl. EPS) Sales Earnings Per Share* 27% decrease Organic: 17% decrease $1.50 $642 $1.10 $561 Q2 Q2 2019 2020 2019 2020 Operating Margin* Free Cash Flow 340 bps decrease 36% increase 24.5% $161 $118 21.1% Q2 Q2 2019 2020 2019 2020 Q2 guidance achieved in challenging market environment *Operating margin and EPS data adjusted for $4.1M in fair value inventory step-up in 2020 and restructuring expenses ($3.8M in Q2 2020; $2.1M in Q2 2019). Q2 2020 EPS additionally adjusted for $8.4M in loss on early debt redemption. 11 IDEX Proprietary & Confidential

 
Q2 Adjusted Operating Income Walk (Dollars in millions) $157 $119 5 3 15 5 (66) 2Q'19 ACT Organic Volume FY19 Cost Actions Discretionary Price/Productivity/Mix Acq / FX 2Q'20 ACT Margin Expected flow Organic flow Total flow Impact through through through 60% 38% 48% $25M of income improvement from cost and price actions IDEX Proprietary & Confidential 12

 
Liquidity (Dollars in millions) FREE CASH FLOW ADJUSTED LEVERAGE(1) $600 $516 200% $477 $500 $423 180% $389 $400 $362 160% $322 138% $300 133% 140% 114% 115% 112% $200 103% 120% $100 100% $- 80% 2015 2016 2017 2018 2019 LTM Free Cash Flow FCF / Net Income Cash on Hand and Term Debt Maturities $900 $800 $800 $746 $700 $600 $500 $500 $400 $350 $300 $200 $100 $100 $100 $- Cash & Cash 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 Equivalents Capital discipline and conservative leverage with liquidity focus Note: LTM period ending Q2 2020 13 IDEX Proprietary & Confidential (1) Adjusted Leverage = Total Debt / Adjusted EBITDA

 
Q3 Summary . Organic revenue expected to be down 12% - 17% . Significant discretionary cost reductions already taken, top line flow through ~45% . Managing short-term volatility while investing for long-term growth . Free cash flow conversion greater than 100% of net income 14 IDEX Proprietary & Confidential

 
Appendix IDEX Proprietary & Confidential

 
Fluid & Metering Technologies (Dollars in millions) Orders Sales Operating Margin* Organic: 20% decrease Organic: 20% decrease 450 bps decrease $242 $246 30.5% $199 $219 26.0% Q2 Q2 Q2 2019 2020 2019 2020 2019 2020 Q2 Sales Mix: Organic -20% Q2 Highlights:  Industrials markets challenged as the slow down anticipated at the start of the year Acquisition 10% has been compounded by COVID  FX -1% Agriculture market remained stable in the quarter  Energy markets remain challenged by low fuel prices, decreasing capital investment Reported Sales -11%  Chemical market soft on delayed projects Volume decline partially mitigated through operational execution and cost control *Operating margin adjusted for $4.1M in fair value inventory step-up in Q2 2020 and restructuring expenses ($1.8M in Q2 2020; $.9M in Q2 2019). 16 IDEX Proprietary & Confidential

 
Health & Science Technologies (Dollars in millions) Orders Sales Operating Margin* Organic: 11% decrease Organic: 10% decrease 180 bps decrease $232 $219 24.6% 22.8% $198 $216 Q2 Q2 Q2 2019 2020 2019 2020 2019 2020 Q2 Sales Mix: Organic -10% Q2 Highlights: Acquisition 4%  Life Sciences continue to perform well driven by DNA Sequencing and Microfluidics; offset by decline in AI market demand FX -1%  Industrial markets across the segment remained challenged in Q2  MPT experiencing strength in Pharma market; some projects being delayed Reported Sales -7%  Sealing Solutions saw strengthening in the Semicon market, offset by weak Automotive and Oil & Gas markets Underlying market condition stabilizing, with projects pushing out to second half *Operating margin adjusted for restructuring expenses ($1.2M in Q2 2020; $.3M in Q2 2019). 17 IDEX Proprietary & Confidential

 
Fire & Safety / Diversified Products (Dollars in millions) Orders Sales Operating Margin* Organic: 24% decrease Organic: 22% decrease 390 bps decrease $168 $164 27.1% 23.2% $126 $127 Q2 Q2 Q2 2019 2020 2019 2020 2019 2020 Q2 Sales Mix: Organic -22% Q2 Highlights:  Fire markets down as municipalities refocus funds; existing OEM backlog solid FX -1%  Rescue project delays negatively impacted demand  Band-IT impacted by declines in Automotive and Aerospace and soft Oil and Reported Sales -23% Gas markets  Dispensing results hindered by India shutdowns and lower levels of capex investments globally Challenging market for Band-IT and Dispensing offset by stable demand in Fire & Safety *Operating margin adjusted for restructuring expenses ($.6M in Q2 2020; $.8M in Q2 2019). 18 IDEX Proprietary & Confidential